An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes
NCT ID: NCT03811288
Last Updated: 2020-06-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
7548 participants
OBSERVATIONAL
2018-12-10
2019-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 Diabetes
NCT03786406
An International Chart Review and Survey for the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients With Type 2 Diabetes Across Countries in the Middle East and Africa
NCT05317845
A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal
NCT03797885
Prevalence and Determinants of Subclinical Cardiovascular Dysfunction in Adults With Type 2 Diabetes Mellitus
NCT03132129
Non-Traditional Cardiovascular Risk Factors in Type 2 Diabetes Mellitus - Ancillary to VA Study of Glycemic Control
NCT00021944
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with type 2 diabetes mellitus (T2DM)
T2DM patients being managed in both primary and specialist care in 10 selected countries.
No treatment given
No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No treatment given
No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female, age more than or equal to 18 years at the time of signing informed consent (in Algeria more than or equal to 19 years; in Japan more than or equal to 20 years).
* Diagnosed with T2DM more than or equal to 180 days prior to the day of signing the informed consent
Exclusion Criteria
* Diagnosed with Type 1 diabetes
* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
* Patients with known congenital heart disease/malformation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Reporting Anchor and Disclosure (1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Algiers, , Algeria
Novo Nordisk Investigational Site
Batna City, , Algeria
Novo Nordisk Investigational Site
Constantine, , Algeria
Novo Nordisk Investigational Site
Tiaret, , Algeria
Novo Nordisk Investigational Site
Tizi Ouzou, , Algeria
Novo Nordisk Investigational Site
Buenos Aires, , Argentina
Novo Nordisk Investigational Site
Buenos Aires, , Argentina
Novo Nordisk Investigational Site
Buenos Aires, , Argentina
Novo Nordisk Investigational Site
Buenos Aires, , Argentina
Novo Nordisk Investigational Site
CABA, , Argentina
Novo Nordisk Investigational Site
CABA, , Argentina
Novo Nordisk Investigational Site
CABA, , Argentina
Novo Nordisk Investigational Site
Chacabuco, , Argentina
Novo Nordisk Investigational Site
Coronel Suárez, , Argentina
Novo Nordisk Investigational Site
Córdoba, , Argentina
Novo Nordisk Investigational Site
Córdoba, , Argentina
Novo Nordisk Investigational Site
Córdoba, , Argentina
Novo Nordisk Investigational Site
Córdoba, , Argentina
Novo Nordisk Investigational Site
Godoy Cruz, , Argentina
Novo Nordisk Investigational Site
Lanús Este, , Argentina
Novo Nordisk Investigational Site
Mar del Plata, , Argentina
Novo Nordisk Investigational Site
Mar del Plata, , Argentina
Novo Nordisk Investigational Site
Morón, , Argentina
Novo Nordisk Investigational Site
Blacktown, New South Wales, Australia
Novo Nordisk Investigational Site
Brookvale, New South Wales, Australia
Novo Nordisk Investigational Site
Campbelltown, New South Wales, Australia
Novo Nordisk Investigational Site
Coffs Harbour, New South Wales, Australia
Novo Nordisk Investigational Site
Maroubra, New South Wales, Australia
Novo Nordisk Investigational Site
Wollongong, New South Wales, Australia
Novo Nordisk Investigational Site
Herston, Queensland, Australia
Novo Nordisk Investigational Site
Morayfield, Queensland, Australia
Novo Nordisk Investigational Site
North Ipswich, Queensland, Australia
Novo Nordisk Investigational Site
Sherwood, Queensland, Australia
Novo Nordisk Investigational Site
Victoria Point, Queensland, Australia
Novo Nordisk Investigational Site
Forest Hill, Victoria, Australia
Novo Nordisk Investigational Site
Moonee Ponds, Victoria, Australia
Novo Nordisk Investigational Site
Parkville, Victoria, Australia
Novo Nordisk Investigational Site
Preston, Victoria, Australia
Novo Nordisk Investigational Site
Ringwood, Victoria, Australia
Novo Nordisk Investigational Site
Fremantle, Western Australia, Australia
Novo Nordisk Investigational Site
Geelong, , Australia
Novo Nordisk Investigational Site
Fortaleza, Ceará, Brazil
Novo Nordisk Investigational Site
Aparecida de Goiânia, Goiás, Brazil
Novo Nordisk Investigational Site
Goiânia, Goiás, Brazil
Novo Nordisk Investigational Site
Belo Horizonte, Minas Gerais, Brazil
Novo Nordisk Investigational Site
Belo Horizonte, Minas Gerais, Brazil
Novo Nordisk Investigational Site
Uberaba, Minas Gerais, Brazil
Novo Nordisk Investigational Site
Campina Grande do Sul, Paraná, Brazil
Novo Nordisk Investigational Site
Curitiba, Paraná, Brazil
Novo Nordisk Investigational Site
Curitiba, Paraná, Brazil
Novo Nordisk Investigational Site
Maringá, Paraná, Brazil
Novo Nordisk Investigational Site
Maringá, Paraná, Brazil
Novo Nordisk Investigational Site
Passo Fundo, Rio Grande do Sul, Brazil
Novo Nordisk Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Novo Nordisk Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Novo Nordisk Investigational Site
Campinas, São Paulo, Brazil
Novo Nordisk Investigational Site
Santo André, São Paulo, Brazil
Novo Nordisk Investigational Site
São Paulo, São Paulo, Brazil
Novo Nordisk Investigational Site
Tatuí, São Paulo, Brazil
Novo Nordisk Investigational Site
Votuporanga, São Paulo, Brazil
Novo Nordisk Investigational Site
Fortaleza, , Brazil
Novo Nordisk Investigational Site
São Paulo, , Brazil
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China
Novo Nordisk Investigational Site
Lanzhou, Gansu, China
Novo Nordisk Investigational Site
Guangzhou, Guangdong, China
Novo Nordisk Investigational Site
Guiyang, Guizhou, China
Novo Nordisk Investigational Site
Wuxi, Jiangsu, China
Novo Nordisk Investigational Site
Shanghai, Shanghai Municipality, China
Novo Nordisk Investigational Site
Luzhou, Sichuan, China
Novo Nordisk Investigational Site
Nanchong, Sichuan, China
Novo Nordisk Investigational Site
Ningbo, Zhejiang, China
Novo Nordisk Investigational Site
Nanjing, , China
Novo Nordisk Investigational Site
Bat Yam, , Israel
Novo Nordisk Investigational Site
Beer-Sheva HaDarom, , Israel
Novo Nordisk Investigational Site
Beersheba, , Israel
Novo Nordisk Investigational Site
Bnei Brak, , Israel
Novo Nordisk Investigational Site
Haifa, , Israel
Novo Nordisk Investigational Site
Holon, , Israel
Novo Nordisk Investigational Site
Jerusalem, , Israel
Novo Nordisk Investigational Site
Jerusalem, , Israel
Novo Nordisk Investigational Site
Kiryat Bialik, , Israel
Novo Nordisk Investigational Site
Nahariya, , Israel
Novo Nordisk Investigational Site
Nazareth, , Israel
Novo Nordisk Investigational Site
Petah Tikva, , Israel
Novo Nordisk Investigational Site
Raanana, , Israel
Novo Nordisk Investigational Site
Safed, , Israel
Novo Nordisk Investigational Site
Tel Aviv, , Israel
Novo Nordisk Investigational Site
Tel Aviv, , Israel
Novo Nordisk Investigational Site
Chiba-shi, Chiba, , Japan
Novo Nordisk Investigational Site
Chuo-ku, Tokyo, , Japan
Novo Nordisk Investigational Site
Ebina-shi, Kanagawa, , Japan
Novo Nordisk Investigational Site
Fukushima, , Japan
Novo Nordisk Investigational Site
Hamamatsu-Shi Shizuoka, , Japan
Novo Nordisk Investigational Site
Hokkaido, , Japan
Novo Nordisk Investigational Site
Kanagawa, , Japan
Novo Nordisk Investigational Site
Kawagoe-shi, Saitama, , Japan
Novo Nordisk Investigational Site
Koshigaya-shi,Saitama, , Japan
Novo Nordisk Investigational Site
Kumamoto, , Japan
Novo Nordisk Investigational Site
Mito-shi, Ibaraki, , Japan
Novo Nordisk Investigational Site
Miyazaki, , Japan
Novo Nordisk Investigational Site
Nishi-ku Sapporo, , Japan
Novo Nordisk Investigational Site
Okawa-shi, Fukuoka, , Japan
Novo Nordisk Investigational Site
Ota-ku, Tokyo, , Japan
Novo Nordisk Investigational Site
Oyama-shi, , Japan
Novo Nordisk Investigational Site
Ōita, , Japan
Novo Nordisk Investigational Site
Shimotsuke-shi, Tochigi, , Japan
Novo Nordisk Investigational Site
Shinjyuku-ku Tokyo, , Japan
Novo Nordisk Investigational Site
Tijuana, Baja California Norte, Mexico
Novo Nordisk Investigational Site
Monclova, Coahuila, Mexico
Novo Nordisk Investigational Site
Celaya, Guanajuato, Mexico
Novo Nordisk Investigational Site
León, Guanajuato, Mexico
Novo Nordisk Investigational Site
Acapulco de Juárez, Guerrero, Mexico
Novo Nordisk Investigational Site
Guadalajara, Jalisco, Mexico
Novo Nordisk Investigational Site
Guadalajara, Jalisco, Mexico
Novo Nordisk Investigational Site
Guadalajara, Jalisco, Mexico
Novo Nordisk Investigational Site
Guadalajara, Jalisco, Mexico
Novo Nordisk Investigational Site
Puerto Vallarta, Jalisco, Mexico
Novo Nordisk Investigational Site
Zapopan, Jalisco, Mexico
Novo Nordisk Investigational Site
Zapopan, Jalisco, Mexico
Novo Nordisk Investigational Site
Cuernavaca, Morelos, Mexico
Novo Nordisk Investigational Site
Benito Juárez, México, D.F., Mexico
Novo Nordisk Investigational Site
Cuauhtémoc, México, D.F., Mexico
Novo Nordisk Investigational Site
Gustavo A. Madero, México, D.F., Mexico
Novo Nordisk Investigational Site
Mexico City, México, D.F., Mexico
Novo Nordisk Investigational Site
Monterrey, Nuevo León, Mexico
Novo Nordisk Investigational Site
Monterrey, Nuevo León, Mexico
Novo Nordisk Investigational Site
San Luis Potosí City, San Luis Potosí, Mexico
Novo Nordisk Investigational Site
Culiacán, Sinaloa, Mexico
Novo Nordisk Investigational Site
Hermosillo, Sonora, Mexico
Novo Nordisk Investigational Site
México, State of Mexico, Mexico
Novo Nordisk Investigational Site
Ciudad Madero, Tamaulipas, Mexico
Novo Nordisk Investigational Site
Aguascalientes, , Mexico
Novo Nordisk Investigational Site
Guadalajara, , Mexico
Novo Nordisk Investigational Site
Mexico City, , Mexico
Novo Nordisk Investigational Site
Monterrey, , Mexico
Novo Nordisk Investigational Site
Querétaro, , Mexico
Novo Nordisk Investigational Site
San Luis Potosí City, , Mexico
Novo Nordisk Investigational Site
Veracruz, , Mexico
Novo Nordisk Investigational Site
Al Ihsa, , Saudi Arabia
Novo Nordisk Investigational Site
Buraidah, , Saudi Arabia
Novo Nordisk Investigational Site
Jeddah, , Saudi Arabia
Novo Nordisk Investigational Site
Riyadh, , Saudi Arabia
Novo Nordisk Investigational Site
Riyadh, , Saudi Arabia
Novo Nordisk Investigational Site
Riyadh, , Saudi Arabia
Novo Nordisk Investigational Site
Ta'if, , Saudi Arabia
Novo Nordisk Investigational Site
Adana, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Ankara, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Ankara, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Ankara, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Antalya, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Edirne, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Elâzığ, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Eskişehir, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Istanbul, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Istanbul, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Istanbul, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Istanbul, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Istanbul, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Izmir, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Kayseri, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Malatya, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Tekirdağ, , Turkey (Türkiye)
Novo Nordisk Investigational Site
Zonguldak, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vencio S, Vianna AGD, da Silva MACF, Precoma DB. Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study. Diabetol Metab Syndr. 2022 Jan 10;14(1):5. doi: 10.1186/s13098-021-00775-9.
Mosenzon O, Alguwaihes A, Leon JLA, Bayram F, Darmon P, Davis TME, Dieuzeide G, Eriksen KT, Hong T, Kaltoft MS, Lengyel C, Rhee NA, Russo GT, Shirabe S, Urbancova K, Vencio S; CAPTURE Study Investigators. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021 Jul 27;20(1):154. doi: 10.1186/s12933-021-01344-0.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1215-4005
Identifier Type: OTHER
Identifier Source: secondary_id
NN2211-4446
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.